Back to News
Market Impact: 0.3
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst EstimatesCompany Fundamentals
BioCryst Pharmaceuticals reported quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.10 by $0.04. Earnings were up from $0.06 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BCRX0.55
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales